AU2004218914A1 - Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases - Google Patents

Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases Download PDF

Info

Publication number
AU2004218914A1
AU2004218914A1 AU2004218914A AU2004218914A AU2004218914A1 AU 2004218914 A1 AU2004218914 A1 AU 2004218914A1 AU 2004218914 A AU2004218914 A AU 2004218914A AU 2004218914 A AU2004218914 A AU 2004218914A AU 2004218914 A1 AU2004218914 A1 AU 2004218914A1
Authority
AU
Australia
Prior art keywords
substituted
phenyl
dna
homo sapiens
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004218914A
Other languages
English (en)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lloyd Sabio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004218914A1 publication Critical patent/AU2004218914A1/en
Priority to AU2008200070A priority Critical patent/AU2008200070A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
AU2004218914A 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases Abandoned AU2004218914A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008200070A AU2008200070A1 (en) 2003-03-11 2008-01-07 Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
US60/453,624 2003-03-11
PCT/EP2004/002460 WO2004080464A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and map kinase related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008200070A Division AU2008200070A1 (en) 2003-03-11 2008-01-07 Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases

Publications (1)

Publication Number Publication Date
AU2004218914A1 true AU2004218914A1 (en) 2004-09-23

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004218914A Abandoned AU2004218914A1 (en) 2003-03-11 2004-03-10 Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
HRP20110839T1 (hr) * 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
TNSN05223A1 (en) 2007-06-11
RU2005131168A (ru) 2006-05-27
HRP20050788A2 (en) 2006-12-31
JP2006519807A (ja) 2006-08-31
ES2318276T3 (es) 2009-05-01
TW200501955A (en) 2005-01-16
EP1603566A1 (en) 2005-12-14
BRPI0408257A (pt) 2006-03-07
WO2004080464A1 (en) 2004-09-23
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
NO20054647D0 (no) 2005-10-10
ZA200506571B (en) 2006-07-26
MXPA05009687A (es) 2005-10-20
RU2325159C2 (ru) 2008-05-27
DE602004019193D1 (de) 2009-03-12
CN1758910A (zh) 2006-04-12
ATE421324T1 (de) 2009-02-15
NO20054647L (no) 2005-12-09
MA27724A1 (fr) 2006-01-02
PL1603566T3 (pl) 2009-07-31
PT1603566E (pt) 2009-04-27
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
US6608071B2 (en) Isoquinoline derivatives with angiogenesis inhibiting activity
EP1165085B1 (en) Phthalazine derivatives for treating inflammatory diseases
MXPA06003340A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa utiles para el tratamiento de enfermedades proliferativas.
CN105189456B (zh) Kras g12c的共价抑制剂
EP1603566B1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
EP0970070B1 (en) Phthalazines with angiogenesis inhibiting activity
US7087624B2 (en) Substituted pyrazole compounds
ES2229340T3 (es) Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
JP6840865B2 (ja) イミダゾピラジン類化合物、その製造方法及び応用
WO2005016344A1 (en) Piperazine derivatives for the treatment of hiv infections
CA2906086A1 (en) Inhibitors of leukotriene a4 hydrolase
JP2023000996A (ja) プロテアーゼ阻害剤としてのケトアミド誘導体
AU2008200070A1 (en) Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted